Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study

NCT00439777 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

4833

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Embolism

Interventions

DRUG: Rivaroxaban (Xarelto, BAY59-7939)
DRUG: Enoxaparin overlapping with and followed by VKA

Sponsor

Bayer

Collaborators

[object Object]